[Positron emission tomography (PET) in the preoperative evaluation of cervical lymph node metastasis of ORL cancer].
The distribution of specific radiolabeled biological compounds in tumor tissues can be imaged by positron emission tomography (PET). The substance used is fluorodeoxyglucose, labeled with the positron emitter fluorine-18. This substance is partly trapped in tumor cells with increased glucose metabolism. This noninvasive imaging technique allows to assess quantitatively and in three dimensions the extent of metastatic disease in ENT cancer. The case presented illustrates the important value we foresee for this new imaging modality in the presurgical staging of cervical metastatic disease of ENT tumors. Sensitivity and specificity of the PET-FDG imaging technique for the loco-regional staging of ENT cancer are, according to preliminary results of an ongoing, prospective clinical study, very high.
Lehmann
W
W
Clinique d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Hôpital cantonal universitaire de Genève.
Benchaou
M
M
Slosman
D O
DO
Townsend
D
D
Ryser
J E
JE
Widmann
J J
JJ
Rüfenacht
D
D
Lacroix
J S
JS
Donath
A
A
D000368:Aged; D003131:Combined Modality Therapy; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D009333:Neck; D009367:Neoplasm Staging; D010039:Otorhinolaryngologic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose
La tomographie par émission de positrons (PET) dans l'évaluation préopératoire des métastases ganglionnaires cervicales des cancers ORL.